Literature DB >> 16967046

Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.

S Rajamani1, L L Eckhardt, C R Valdivia, C A Klemens, B M Gillman, C L Anderson, K M Holzem, B P Delisle, B D Anson, J C Makielski, C T January.   

Abstract

BACKGROUND AND
PURPOSE: Fluoxetine (Prozac) is a widely prescribed drug in adults and children, and it has an active metabolite, norfluoxetine, with a prolonged elimination time. Although uncommon, Prozac causes QT interval prolongation and arrhythmias; a patient who took an overdose of Prozac exhibited a prolonged QT interval (QTc 625 msec). We looked for possible mechanisms underlying this clinical finding by analysing the effects of fluoxetine and norfluoxetine on ion channels in vitro. EXPERIMENTAL APPROACH: We studied the effects of fluoxetine and norfluoxetine on the electrophysiology and cellular trafficking of hERG K+ and SCN5A Na+ channels heterologously expressed in HEK293 cells. KEY
RESULTS: Voltage clamp analyses employing square pulse or ventricular action potential waveform protocols showed that fluoxetine and norfluoxetine caused direct, concentration-dependent, block of hERG current (IhERG). Biochemical studies showed that both compounds also caused concentration-dependent reductions in the trafficking of hERG channel protein into the cell surface membrane. Fluoxetine had no effect on SCN5A channel or HEK293 cell endogenous current. Mutations in the hERG channel drug binding domain reduced fluoxetine block of IhERG but did not alter fluoxetine's effect on hERG channel protein trafficking. CONCLUSIONS AND IMPLICATIONS: Our findings show that both fluoxetine and norfluoxetine at similar concentrations selectively reduce IhERG by two mechanisms, (1) direct channel block, and (2) indirectly by disrupting channel protein trafficking. These two effects are not mediated by a single drug binding site. Our findings add complexity to understanding the mechanisms that cause drug-induced long QT syndrome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16967046      PMCID: PMC2014667          DOI: 10.1038/sj.bjp.0706892

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  [Torsade de pointes after poisoning with fluoxetine alone].

Authors:  T Lherm; F Lottin; D Larbi; M Bray; C Legall; D Caen
Journal:  Presse Med       Date:  2000-02-19       Impact factor: 1.228

2.  Fluoxetine toxicity in a breastfed infant.

Authors:  T W Hale; S Shum; M Grossberg
Journal:  Clin Pediatr (Phila)       Date:  2001-12       Impact factor: 1.168

3.  Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents.

Authors:  Harry J Witchel; Vijay K Pabbathi; Giovanna Hofmann; Ashok A Paul; Jules C Hancox
Journal:  FEBS Lett       Date:  2002-02-13       Impact factor: 4.124

4.  Cardiac arrhythmia in a newborn infant associated with fluoxetine use during pregnancy.

Authors:  Gadi Abebe-Campino; Dafna Offer; Bracha Stahl; Paul Merlob
Journal:  Ann Pharmacother       Date:  2002-03       Impact factor: 3.154

5.  The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels.

Authors:  Dierk Thomas; Bernd Gut; Gunnar Wendt-Nordahl; Johann Kiehn
Journal:  J Pharmacol Exp Ther       Date:  2002-02       Impact factor: 4.030

6.  The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations.

Authors:  Eckhard Ficker; Carlos A Obejero-Paz; Shuxia Zhao; Arthur M Brown
Journal:  J Biol Chem       Date:  2001-12-10       Impact factor: 5.157

7.  Fluoxetine (Prozac) as a cause of QT prolongation.

Authors:  P Varriale
Journal:  Arch Intern Med       Date:  2001-02-26

8.  Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients.

Authors:  Lesley H Curtis; Truls Østbye; Veronica Sendersky; Steve Hutchison; Nancy M Allen LaPointe; Sana M Al-Khatib; Sally Usdin Yasuda; Peter E Dans; Alan Wright; Robert M Califf; Raymond L Woosley; Kevin A Schulman
Journal:  Am J Med       Date:  2003-02-01       Impact factor: 4.965

9.  A structural basis for drug-induced long QT syndrome.

Authors:  J S Mitcheson; J Chen; M Lin; C Culberson; M C Sanguinetti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

10.  A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine.

Authors:  Carmen R Valdivia; Michael J Ackerman; David J Tester; Tomoyuki Wada; Jorge McCormack; Bin Ye; Jonathan C Makielski
Journal:  Cardiovasc Res       Date:  2002-08-01       Impact factor: 10.787

View more
  71 in total

Review 1.  Revealing the structural basis of action of hERG potassium channel activators and blockers.

Authors:  Matthew Perry; Michael Sanguinetti; John Mitcheson
Journal:  J Physiol       Date:  2010-07-19       Impact factor: 5.182

Review 2.  Drug-induced long QT syndrome.

Authors:  Prince Kannankeril; Dan M Roden; Dawood Darbar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 3.  hERG quality control and the long QT syndrome.

Authors:  Brian Foo; Brittany Williamson; Jason C Young; Gergely Lukacs; Alvin Shrier
Journal:  J Physiol       Date:  2016-02-09       Impact factor: 5.182

4.  The protease inhibitor atazanavir blocks hERG K(+) channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane.

Authors:  Sheng-na Han; Xiao-yan Sun; Zhao Zhang; Li-rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2015-03-23       Impact factor: 6.150

Review 5.  Editors' review of 2006 and the BJCP prize.

Authors:  Jeffrey K Aronson; Martin S Lennard; James M Ritter; Evan J Begg; Lionel D Lewis; Michael Schachter
Journal:  Br J Clin Pharmacol       Date:  2007-01       Impact factor: 4.335

6.  Inhibition of cloned hERG potassium channels by risperidone and paliperidone.

Authors:  Hong Joon Lee; Jin-Sung Choi; Bok Hee Choi; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-03-06       Impact factor: 3.000

Review 7.  Mechanisms of cardiac potassium channel trafficking.

Authors:  David F Steele; Jodene Eldstrom; David Fedida
Journal:  J Physiol       Date:  2007-04-05       Impact factor: 5.182

8.  Intracellular potassium stabilizes human ether-à-go-go-related gene channels for export from endoplasmic reticulum.

Authors:  Lu Wang; Adrienne T Dennis; Phan Trieu; Francois Charron; Natalie Ethier; Terence E Hebert; Xiaoping Wan; Eckhard Ficker
Journal:  Mol Pharmacol       Date:  2009-01-12       Impact factor: 4.436

9.  Escitalopram block of hERG potassium channels.

Authors:  Yun Ju Chae; Ji Hyun Jeon; Hong Joon Lee; In-Beom Kim; Jin-Sung Choi; Ki-Wug Sung; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-09-18       Impact factor: 3.000

10.  Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells.

Authors:  J Jehle; E Ficker; X Wan; I Deschenes; J Kisselbach; F Wiedmann; I Staudacher; C Schmidt; P A Schweizer; R Becker; H A Katus; D Thomas
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.